Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy
New Eveo system is designed to raise CAR-T output, cut manufacturing costs, and ease cleanroom bottlenecks
-
1
Sartorius launched the Eveo Cell Therapy Platform to enhance the scalability of autologous cell therapies like CAR-T.
-
2
The platform integrates multiple processes into a closed, modular workflow, allowing parallel processing of patient batches.
-
3
In a pilot, a single operator processed eight patient batches in a space typically used for two, significantly increasing output.
-
4
Sartorius estimates the platform could produce over 350 doses annually, reducing CAR-T manufacturing costs by about 90%.
-
5
Orders for the Eveo Cell Therapy Platform will begin in September 2026, with deliveries expected in 2027.
